Pharmacometabolomics Biomarkers for L-Carnitine Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis face challenges in diagnosis, delayed recognition of organ dysfunction, and a poorly characterized biological phenotype, limiting the ability to select patients who will benefit from specific treatments and titrate dosing appropriately, leading to compromised patient outcomes.
Innovation Solution
A pharmacometabolomics strategy that uses metabolite levels in patient samples to identify sepsis patients likely to respond to L-carnitine treatment, employing biomarkers such as ketone bodies, acetylcarnitine, and the acetylcarnitine:carnitine ratio to differentiate 'carnitine responders' from 'non-responders', enabling personalized therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing diagnostic technologies and general sepsis treatments are used, then standard care can be provided to all patients, but patient outcomes are compromised due to inability to select patients who will benefit from specific treatments
Solution Approach 1:
The invention segments sepsis patients into distinct metabolic phenotypes (e.g., high ketone bodies vs. low ketone bodies) based on metabolite level measurements. This segmentation allows clinicians to identify which patients are likely to respond to L-carnitine therapy versus those who are not, thereby improving treatment selection and outcomes without requiring a completely new diagnostic system.
Solution Approach 2:
The invention changes the diagnostic parameter from general clinical assessment to specific metabolite level measurements (ketone bodies, acetylcarnitine, carnitine ratios). By measuring these metabolic parameters, the system can objectively identify patient subgroups with specific metabolic profiles that predict treatment response, enabling personalized therapy decisions.
2Adaptability or versatility
If pharmacogenomics approaches are used to predict drug response, then personalized treatment selection is attempted, but success is limited due to inconsistencies and limited understanding of biological indications
Solution Approach 1:
The invention substitutes pharmacogenomics (which relies on genetic variations and has limited predictive power for acute drug response) with pharmacometabolomics (which measures actual metabolic state). By measuring metabolite levels that directly reflect current metabolic dysfunction, the system provides more reliable and consistent prediction of L-carnitine response compared to genetic approaches.
Solution Approach 2:
The invention changes from measuring genetic parameters (which are static and have limited correlation with acute drug response) to measuring metabolic parameters (ketone bodies, acetylcarnitine levels) that dynamically reflect the patient's current physiological state and predict treatment response more accurately.
3Reliability
If L-carnitine treatment is administered to all sepsis patients, then potential benefit to all patients is maximized, but resources are wasted on patients unlikely to respond and adverse reactions may occur
Solution Approach 1:
The invention performs preliminary metabolic phenotyping by measuring ketone bodies and acetylcarnitine levels before administering L-carnitine treatment. This preliminary assessment identifies patients who are likely to respond to therapy, allowing clinicians to pre-select appropriate candidates and avoid administering the drug to patients unlikely to benefit, thereby optimizing resource allocation and reducing waste.
4Adaptability or versatility
If comprehensive metabolite measurement is performed to identify responders, then personalized treatment prediction is achieved, but diagnostic complexity and cost increase
Solution Approach 1:
The invention extracts and measures only the specific metabolites most relevant to L-carnitine response (ketone bodies, acetylcarnitine, and the acetylcarnitine:carnitine ratio) rather than performing comprehensive metabolite profiling. This focused approach achieves personalized treatment prediction by concentrating on the key metabolic indicators that have been shown to predict treatment response, thereby reducing diagnostic complexity while maintaining predictive accuracy.
Data Source
AI summary
Provided herein is technology relating to treatment of sepsis and particularly, but not exclusively, to methods for predicting a response of a sepsis patient to treatment with L-carnitine.